Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + Rituximab vs Low-dose Rituximab in Refractory ITP
NCT01525836Phase 3Completed
- Sponsor
- Shandong University
- Start
- May 2011
- Primary completion
- Dec 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human thrombopoietin in immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoints: Evaluation of platelet response (Complete Response) at 3 months, Evaluation of platelet response (Response) at 3 months and 2 more. Started May 2011; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01525836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01525836.